Vir Biotechnology Aktie
WKN DE: A2PS0P / ISIN: US92764N1028
25.11.2024 15:30:00
|
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir Biotechnology’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125578049/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vir Biotechnology Inc Registered Shsmehr Nachrichten
25.02.25 |
Ausblick: Vir Biotechnology verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
30.10.24 |
Ausblick: Vir Biotechnology mit Zahlen zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Vir Biotechnology Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Vir Biotechnology Inc Registered Shs | 6,02 | -4,29% |
|